CN Stock MarketDetailed Quotes

301333 R&G PharmaStudies

Watchlist
  • 58.07
  • -3.56-5.78%
Market Closed Nov 1 15:00 CST
5.61BMarket Cap46.31P/E (TTM)

About R&G PharmaStudies Company

As a well-known CRO company rooted in China and facing the world, the company takes the purpose of “for human health”, adheres to the “scientific, professional and innovative” service concept, provides global pharmaceutical companies with comprehensive and full-chain CRO services in clinical research and development, improving the success rate of drug development, reducing risks, saving costs, and shortening the cycle, and has been widely praised in the industry. The company's main business is to provide comprehensive integrated services for pharmaceutical companies and scientific research institutions around the world throughout the clinical research and development process. The company's main products include clinical trial operation services (“CO services”), clinical trial site management services (“SMO services”), biological sample testing services (“BA services”), data management and statistical analysis services (“DM/ST services”), clinical trial consulting services, and clinical pharmacology services (“CP services”).

Company Profile

Short Name-A诺思格
Symbol-A301333
Company NameR&G PharmaStudies Co., Ltd.
Listing DateAug 2, 2022
Issue Price78.88
Shares Offered15.00M share(s)
FoundedAug 22, 2008
Legal Representativejie wu
General Managerjie wu
Secretaryshuqi li
Accounting FirmGrant Tung Certified Public Accountants (Special General Partnership)
Legal CounselBeijing Junhe Law Firm
Employees597
Phone010-88019152
Office Address11th Floor, North Tower B, Huatong Building, No. 19 Chegongzhuang West Road, Haidian District, Beijing
Zip Code100048
Registered AddressNo. 518, Chuangyi West Road, East District, Tongzhou Economic Development Zone, Beijing
Fax010-88019978
Emailir@rg-pharma.com
Business License110000450063770
BusinessResearch and development of pharmaceuticals, health products, and medical devices; providing technical advice, technical training, technical services and investment consulting for the pharmaceutical industry (not limited to special licensing services); technology import and export; import and export of goods; management and statistical analysis of research data; engaging in information technology and business process outsourcing services such as data processing by outsourcing services; translation services. (The above does not cover goods managed by state-owned trade; if the goods are managed by quotas or licenses, the application shall be processed in accordance with the relevant national regulations) (For projects subject to approval according to law, business activities are carried out in accordance with the approved content after approval by the relevant departments.)

Company Executives

  • Name
  • Position
  • Salary
  • jie wu
  • Chairman, Directors, General Manager, Nomination Committee Members, Strategy Committee Convener, Member of the Remuneration and Assessment Committee
  • 1.44M
  • shuqi li
  • Directors, Board Secretary, Deputy General Manager, Member of the Strategy Committee
  • 567.50K
  • leyan teng
  • Directors, Deputy General Manager
  • 680.80K
  • wei wang
  • Directors, Deputy General Manager
  • 832.00K
  • hongbei zheng
  • Directors
  • --
  • qian chen
  • Directors
  • --
  • wen sun
  • Independent Directors, Remuneration and Assessment Committee Convener, Audit Committee Member, Nomination Committee Members
  • --
  • feng li
  • Independent Directors, Audit Committee Convener, Member of the Remuneration and Assessment Committee
  • --
  • haohai shi
  • Independent Directors, Audit Committee Member, Member of the Strategy Committee, Nomination Committee Convener
  • --
  • hong guan
  • Chairman of the Supervisory Board, Employee Supervisors
  • 398.90K
  • weiguo zhang
  • Auditors
  • 478.90K
  • yan zheng
  • Auditors
  • 758.90K
  • ping liu
  • Deputy General Manager
  • 1.05M
  • jigang li
  • Deputy General Manager
  • 767.50K
  • gang chen
  • Deputy General Manager
  • 1.80M
  • qian zhao
  • Chief Financial Officer
  • 966.40K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
CN
Overall
Symbol
Latest Price
% Chg

No Data